Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
Ontology highlight
ABSTRACT: Infliximab, an anti-TNF-alpha monoclonal antibody, is an effective treatment for ulcerative colitis (UC) with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-TNF-alpha is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in UC. Keywords: drug response
ORGANISM(S): Homo sapiens
PROVIDER: GSE14580 | GEO | 2010/01/07
SECONDARY ACCESSION(S): PRJNA111695
REPOSITORIES: GEO
ACCESS DATA